Editorial: future frontiers in the management of metastatic colorectal cancer

Metastatic colorectal cancer (mCRC) remains a major challenge in oncology, with a five-year survival rate of only 14%, underscoring the need for innovative and effective treatments. Despite advances in surgery, chemotherapy, and targeted therapies, mCRC often remains incurable, highlighting the critical need for continued research and development in treatment modalities. In recent years, significant progress has been made in the treatment of mCRC, with the introduction of novel chemotherapeutic and targeted therapy agents.